



# Marksans Pharma Ltd.

## MARKSANS PHARMA LIMITED

CIN: L24110MH1992PLC066364

**Registered Office:** 11<sup>th</sup> Floor, Grandeur, Veera Desai Extension Road,  
Oshiwara, Andheri (W), Mumbai – 400053.

**Phone.No.** 022-40012000 **Fax No.** 022-40012011

E-mail: [companysecretary@marksanspharma.com](mailto:companysecretary@marksanspharma.com), Website: [www.marksanspharma.com](http://www.marksanspharma.com)

### CORRIGENDUM TO EGM NOTICE

We draw kind attention of all concerned towards our Notice dated June 15, 2021 calling an Extra-ordinary General Meeting of the Company (**NOTICE**) to be held on Friday, the 9<sup>th</sup> July, 2021 through Video Conferencing / Other Audio Visual Means (VC) at 09.00 a.m. sent through permitted mode on 16<sup>th</sup> June, 2021.

This is with regard to Clause VII of Item No.1 of the Explanatory Statement annexed to the NOTICE.

In the table of the said Clause VII of Item No. 1 of the Explanatory Statement in column no. 3, Identity of Ultimate Beneficial Owners of OrbiMed Asia IV Mauritius FVCI Limited is wrongly mentioned as NA. The said table is reproduced hereinbelow with identity of ultimate beneficial owners of OrbiMed Asia IV Mauritius FVCI Limited:

**VII. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/ or who ultimately control the proposed allottees, the percentage of post preferential issue capital that may be held by them:**

Sr. No.	Name & Category of proposed allottee	Identity of Ultimate Beneficial Owners	No. & % of equity shares held prior to the preferential allotment		No. of warrants to be issued and allotted	No. & % of equity share post issue (After exercise of Warrants)*	
			No. of shares	%	No. of warrants	No. of shares	%
	<b>Promoter</b>						
1	Mr. Mark Saldhana	N.A	19,74,91,553	48.25	10,00,000	19,84,91,553	43.18
	<b>Non-Promoter</b>						
2	OrbiMed Asia IV Mauritius FVCI Limited	1. Sam Block III 2. Ryan Loggie 3. Ashish D. Jagarnath 4. Chettensingh Awotarsingh 5. Kumaren Appavoo	NIL	NIL	4,93,24,324	4,93,24,324	10.73
<b>Total</b>					<b>5,03,24,324</b>		

\*Assuming all the Warrants shall be converted into Equity Shares of the Company.

All concerned are requested to read the above details in the place of Clause VII of Item No. 1 of the Explanatory Statement on page no. 09 of the NOTICE.

We regret the inconvenience caused to the Members and all other concerned in this regard.

Kindly note that this Corrigendum to the **NOTICE** is issued by order of the Board to all the Members of the Company and Stock Exchanges as well as others entitled thereto pursuant to section 101 of the Companies Act, 2013. Thus, the **NOTICE** shall always be read with this Corrigendum.

The Corrigendum to the **NOTICE** of the Extra-ordinary General Meeting is being uploaded at the Company's website viz [www.marksanspharma.com](http://www.marksanspharma.com). Please note that e-voting will commence from 09.00 a.m. on Tuesday, July 6, 2021 to 5.00 p.m. on Thursday, July 8, 2021.

For **Marksans Pharma Limited**

Harshavardhan Panigrahi  
**Company Secretary**

Date: 30<sup>th</sup> June, 2021  
Place: Mumbai